bioRxivGeneticsPreprint
Gene replacement therapy for Piga GPI-anchor deficiency in the developing nervous system
Jennifer L. WattsiD, Shibi B. LikhiteiD, Yoshiko MurakamiiD, Taroh KinoshitaiD, Kathrin MeyeriD, Rolf W. StottmanniD
Abstract
Glycosylphosphatidylinositol (GPI) anchors are a class of post-translational modifications observed on over 150 proteins. Pathogenic variants in the GPI biosynthesis enzyme, PIGA, in humans are associated with several brain anomalies such as hypomyelination, cerebellar hypoplasia, ataxic gait, and can lead to premature mortality. We previously genetically deleted Piga from the embryonic mouse brain which led to early postnatal death and significant structural brain malformations similar to those observed in humans with PIGA variants. The current treatment options for PIGA patients only manage symptoms and provides palliative care, demonstrating a need for new therapeutic options. We employed an AAV9-mediated PIGA gene-replacement (AAV9-hPIGA) strategy to assess the efficacy of gene therapy in the brain. We show that a single intracerebroventricular treatment on the first day of life successfully rescued survival rates, structural brain anomalies, and neurological impairments. Additionally, we used mass spectrometry to identify and quantify GPI-anchored proteins in untreated and treated mutant mice. We found that AAV9- hPIGA treatment restored GPI-anchored protein levels in mutant animals. These investigations enhance our understanding of GPI-anchored protein production during brain development and contribute to the development of a more effective intervention for PIGA-related symptoms. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=165 SRC="FIGDIR/small/693709v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@32038dorg.highwire.dtl.DTLVardef@1875eb5org.highwire.dtl.DTLVardef@5abfe8org.highwire.dtl.DTLVardef@1ed5719_HPS_FORMAT_FIGEXP M_FIG C_FIG Key PointsO_LIA single AAV9-hPIGA injection rescues Piga-related phenotypes including survival and structural brain defects C_LIO_LIAAV9-hPIGA treatment rescued long-term ataxia phenotypes in Piga mutants C_LIO_LINeuronal GPI-anchored protein levels in Piga mutants are increased with AAV9- hPIGA gene replacement C_LI
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic Dissection of the role of Piga and Pgap2 in the embryonic mouse brain
Jennifer L. Watts, Jesus M. Leal, Rolf W. Stottmann·iSciencePeer-reviewed·Jun 1, 2026
- CNS Glycosylphosphatidylinositol Deficiency Results in Delayed White Matter Development, Ataxia, and Premature Death in a Novel Mouse Model
Marshall Lukacs, Lauren E. Blizzard, Rolf W. Stottmann·Human Molecular GeneticsPeer-reviewed·Mar 11, 2020
- Limb-clasping, cognitive deficit and increased vulnerability to kainic acid -induced seizures in neuronal GPI anchor deficiency mouse models
Lenin C. Kandasamy, Mina Tsukamoto, … Qi Zhang·Human Molecular GeneticsPeer-reviewed·Feb 15, 2021
- A CRISPR-Cas9-engineered mouse model for GPI-anchor deficiency mirrors human phenotypes and exhibits hippocampal synaptic dysfunctions
Miguel Rodríguez de los Santos, Marion Rivalan, … Peter Michael Krawitz·Proceedings of the National Academy of SciencesPeer-reviewed·Jan 5, 2021
- Drosophila models of PIGA-CDG mirror patient phenotypes
Holly J. Thorpe, Katie G Owings, … Clement Y. Chow·bioRxiv·Oct 27, 2023
- Ethanolamine phosphate on the second mannose as bridge in GPI anchored proteins: Towards understanding inherited PIGG deficiency
Mizuki Ishida, Yuta Maki, … Yoshiko Murakami·bioRxiv·Nov 26, 2020